RXRX → $2.70 by Aug 25, 2026.

Ticker: **RXRX** Current area: **around $2.97** Bias: **still bearish short-term, but not blindly bearish** Primary downside target: **$2.70** Stretch target: **$2.50–$2.60** Invalidation: **reclaim and hold above $3.25–$3.35** Yesterday’s RXRX post got a lot of attention, so I want to tighten the thesis and address the biggest pushback directly. The fair criticism is this: RXRX is not an “imminent bankruptcy” short. That was never the argument. The company reported **$665.2M in cash, cash equivalents, and restricted cash as of March 31, …